

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in this application:

Listing of Claims

1. – 11. (Canceled)

12. (New) A method of treating in a mammal, including a human, pains which are accompanied by an increase in muscle tone, comprising administering to a patient in need thereof a therapeutically effective amount of a combination of retigabine or a therapeutically utilizable salt thereof with a sodium channel-inhibiting or -influencing substance or a therapeutically utilizable salt thereof.

13. (New) The method of claim 12, wherein said sodium channel-inhibiting or -influencing substance is selected from tolperisone, eperisone, silperisone, riluzole, propafenone, lidocaine, flecainide, and metixen, or pharmaceutically utilizable salts thereof.

14. (New) The method of claim 12, wherein said sodium channel-inhibiting or -influencing substance is selected from tolperisone, eperisone, silperisone, and other tolperisone analogs, and pharmaceutically utilizable salts thereof.

15. (New) A method of treating in a mammal, including a human, pains which are accompanied by an increase in muscle tone, comprising administering to a patient in need thereof a therapeutically effective amount of a combination of retigabine with tolperisone, eperisone, silperisone, or another tolperisone analog, or a pharmaceutically utilizable salt thereof.

16. (New) The method of claim 12, where said pains are associated with neuralgias.

17. (New) The method of claim 12, where said pains are associated with arthritis and arthrosis.

18. (New) The method of claim 12, where said pains are associated with chronic or episodic tension headache.

19. (New) The method of claim 12, where said pains originate from a cause selected from lower spastic paraparesis syndrome, disturbances of the spinal blood circulation, and cerebral paralysis involving lower spastic paresis.

20. (New) The method of claim 12, where said pains originate from a cause selected from lower paraspasm, transverse myelitis, multiple sclerosis, heritable inferior spastic paraplegia (“Stuempel paraplegia”).

21. (New) The method of claim 12, where said pains are associated with tetraparesis in connection with cervical myelopathy, cervical brachialgia or vertebral dysplasia.

22. (New) The method of claim 12, where said pains are associated with Parkinson's disease.

23. (New) The method of claim 12, where said combination is administered orally, rectally, intravenously, transdermally, subcutaneously, or intracutaneously.

24. (New) The method of claim 12, wherein said sodium channel-inhibiting or -influencing substance or therapeutically utilizable salt thereof is administered simultaneously with retigabine.

25. (New) The method of claim 12, wherein retigabine, or a therapeutically utilizable salt thereof, and said sodium channel-inhibiting or -influencing substance are administered separately or consecutively.